A Randomized, International, Open-Label Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) Experience Grade 2 or Higher AEs in the First 12 Months of Treatment With Vandetanib
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 11 Dec 2017
At a glance
- Drugs Vandetanib (Primary)
- Indications Adenocarcinoma; Thyroid cancer
- Focus Adverse reactions; Registrational
- Sponsors AstraZeneca; Sanofi Genzyme
- 02 Nov 2017 Planned End Date changed from 14 Mar 2018 to 31 Dec 2019.
- 07 Jul 2017 Planned End Date changed from 1 Dec 2017 to 14 Mar 2018.
- 19 Jan 2017 This trial has been completed in Belgium as per European Clinical Trials Database.